Orchestra BioMed Holdings (OBIO) Return on Equity (2022 - 2025)
Orchestra BioMed Holdings (OBIO) has disclosed Return on Equity for 4 consecutive years, with 3.41% as the latest value for Q3 2025.
- On a quarterly basis, Return on Equity fell 214.0% to 3.41% in Q3 2025 year-over-year; TTM through Sep 2025 was 3.41%, a 214.0% decrease, with the full-year FY2024 number at 1.21%, down 42.0% from a year prior.
- Return on Equity was 3.41% for Q3 2025 at Orchestra BioMed Holdings, up from 8.13% in the prior quarter.
- In the past five years, Return on Equity ranged from a high of 0.37% in Q2 2023 to a low of 8.13% in Q2 2025.
- A 4-year average of 1.78% and a median of 0.97% in 2024 define the central range for Return on Equity.
- Peak YoY movement for Return on Equity: decreased -27bps in 2023, then plummeted -703bps in 2025.
- Orchestra BioMed Holdings' Return on Equity stood at 0.41% in 2022, then tumbled by -67bps to 0.69% in 2023, then crashed by -125bps to 1.54% in 2024, then crashed by -122bps to 3.41% in 2025.
- Per Business Quant, the three most recent readings for OBIO's Return on Equity are 3.41% (Q3 2025), 8.13% (Q2 2025), and 2.66% (Q1 2025).